Free Trial
NASDAQ:GYRE

Gyre Therapeutics Q3 2025 Earnings Report

Gyre Therapeutics logo
$8.20 +0.31 (+3.93%)
As of 01:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gyre Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
$0.05
Beat/Miss
N/A
One Year Ago EPS
N/A

Gyre Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$32.93 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gyre Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 13, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Gyre Therapeutics Earnings Headlines

October 16 Changes the Microchip Game — and Investing
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.tc pixel
High Growth US Tech Stocks To Watch In October 2025
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE) is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas. By leveraging its platform to validate novel targets and generate lead candidates, the company aims to address unmet medical needs where dysregulated lipid environments drive disease progression.

Headquartered in South San Francisco, California, Gyre Therapeutics was founded in 2021 and completed its initial public offering on the Nasdaq Global Market under the ticker symbol GYRE in mid-2023. Operating primarily in the United States, the company collaborates with academic researchers and industry partners to advance its discovery efforts. Through its innovative focus on membrane biochemistry, Gyre seeks to build a diversified portfolio of first-in-class small-molecule therapies.

View Gyre Therapeutics Profile

More Earnings Resources from MarketBeat